Article date: January 0001
By: MH Jäntti, J Putula, P Somerharju, MA Frohman, JP Kukkonen in Volume 165, Issue 4b, pages 1109-1123
BACKGROUND AND PURPOSE
Orexin receptors potently signal to lipid messenger systems, and our previous studies have suggested that PLD would be one of these. We thus wanted to verify this by direct measurements and clarify the molecular mechanism of the coupling.
EXPERIMENTAL APPROACH
Orexin receptor‐mediated PLD activation was investigated in CHO cells stably expressing human OX1 orexin receptors using [14C]‐oleic acid‐prelabelling and the transphosphatidylation assay.
KEY RESULTS
Orexin stimulation strongly increased PLD activity – even more so than the phorbol ester TPA (12‐O‐tetradecanoyl‐phorbol‐13‐acetate), a highly potent activator of PLD. Both orexin and TPA responses were mediated by PLD1. Orexin‐A and ‐B showed approximately 10‐fold difference in potency, and the concentration–response curves were biphasic. Using pharmacological inhibitors and activators, both orexin and TPA were shown to signal to PLD1 via the novel PKC isoform, PKCδ. In contrast, pharmacological or molecular biological inhibitors of Rho family proteins RhoA/B/C, cdc42 and Rac did not inhibit the orexin (or the TPA) response, nor did the molecular biological inhibitors of PKD. In addition, neither cAMP elevation, Gαi/o nor Gβγ seemed to play an important role in the orexin response.
CONCLUSIONS AND IMPLICATIONS
Stimulation of OX1 receptors potently activates PLD (probably PLD1) in CHO cells and this is mediated by PKCδ but not other PKC isoforms, PKDs or Rho family G‐proteins. At present, the physiological significance of orexin‐induced PLD activation is unknown, but this is not the first time we have identified PKCδ in orexin signalling, and thus some specific signalling cascade may exist between orexin receptors and PKCδ.
DOI: 10.1111/j.1476-5381.2011.01565.x
View this article